Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd - Asset Resilience Ratio

Latest as of March 2025: 11.06%

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd (688505) has an Asset Resilience Ratio of 11.06% as of March 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Shanghai Fudan-Zhangjiang Bio-Pharmaceut (688505) working capital ratio to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

CN¥280.00 Million
≈ $40.97 Million USD Cash + Short-term Investments

Total Assets

CN¥2.53 Billion
≈ $370.37 Million USD All company assets

Resilience Assessment

Moderate
Financial Resilience Level

Asset Resilience Ratio Trend (2005–2022)

This chart shows how Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Shanghai Fudan-Zhangjiang Bio-Pharmaceut assets under control.

Liquid Assets Composition Over Time

This chart breaks down Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read 688505 total debt and obligations for a breakdown of total debt and financial obligations.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CN¥0.00 0%
Short-term Investments CN¥280.00 Million 11.06%
Total Liquid Assets CN¥280.00 Million 11.06%

Asset Resilience Insights

  • Moderate Liquidity: Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd has 11.06% of assets in liquid form.
  • While adequate for normal operations, this level may limit flexibility during economic stress.
  • The company has significant short-term investments, indicating active treasury management.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Industry Peers by Asset Resilience Ratio

Compare Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Torrent Pharmaceuticals Limited
NSE:TORNTPHARM
Drug Manufacturers - Specialty & Generic 2.79%
Swedish Orphan Biovitrum AB (publ)
ST:SOBI
Drug Manufacturers - Specialty & Generic 1.54%
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
Drug Manufacturers - Specialty & Generic 0.20%
Beijing Tongrentang Co Ltd
SHG:600085
Drug Manufacturers - Specialty & Generic 2.51%
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858
Drug Manufacturers - Specialty & Generic 3.47%
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423
Drug Manufacturers - Specialty & Generic 20.44%
Harbin Pharmaceutical Group Co Ltd
SHG:600664
Drug Manufacturers - Specialty & Generic 0.97%
Kangmei Pharmaceutical Co Ltd
SHG:600518
Drug Manufacturers - Specialty & Generic 0.00%

Annual Asset Resilience Ratio for Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd (2005–2022)

The table below shows the annual Asset Resilience Ratio data for Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2022-12-31 1.12% CN¥33.32 Million
≈ $4.88 Million
CN¥2.98 Billion
≈ $435.48 Million
+1.12pp
2011-12-31 0.00% CN¥11.00K
≈ $1.61K
CN¥358.88 Million
≈ $52.52 Million
-0.04pp
2010-12-31 0.05% CN¥143.00K
≈ $20.93K
CN¥304.15 Million
≈ $44.51 Million
+0.02pp
2006-12-31 0.03% CN¥38.00K
≈ $5.56K
CN¥145.02 Million
≈ $21.22 Million
-0.31pp
2005-12-31 0.33% CN¥475.00K
≈ $69.51K
CN¥142.91 Million
≈ $20.91 Million
--
pp = percentage points

About Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd

SHG:688505 China Drug Manufacturers - Specialty & Generic
Market Cap
$872.35 Million
CN¥5.96 Billion CNY
Market Cap Rank
#9627 Global
#2486 in China
Share Price
CN¥8.48
Change (1 day)
+3.54%
52-Week Range
CN¥6.68 - CN¥9.37
All Time High
CN¥39.80
About

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd., engages in the research, development, manufacture, and sale of biopharmaceutical products in the People's Republic of China. It offers photodynamic technology drugs, such as aminolevulinic acid hydrochloride and hemoporfin for Injection; doxorubicin liposome under the Libord brand; genetic engineering drugs; and oral solid preparation technol… Read more